Positive Allosteric Modulation of Kv Channels by Sevoflurane: Insights into the Structural Basis of Inhaled Anesthetic Action.

Qiansheng Liang  
*Department of Neuroscience, Sidney Kimmel Medical College of Thomas Jefferson University*

Warren D Anderson  
*Department of Neuroscience, Sidney Kimmel Medical College of Thomas Jefferson University*

Shelly T Jones  
*Department of Neuroscience, Sidney Kimmel Medical College of Thomas Jefferson University*

Caio S Souza  
*Laboratório de Biologia Teórica e Computacional, Departamento de Biologia Celular, Universidade de Brasília*

Juliana M Hosoume  
*Laboratório de Biologia Teórica e Computacional, Departamento de Biologia Celular, Universidade de Brasília*

Follow this and additional works at: [https://jdc.jefferson.edu/department_neuroscience](https://jdc.jefferson.edu/department_neuroscience)

Let us know how access to this document benefits you

**Recommended Citation**

Liang, Qiansheng; Anderson, Warren D; Jones, Shelly T; Souza, Caio S; Hosoume, Juliana M; Treptow, Werner; and Covarrubias, Manuel, "Positive Allosteric Modulation of Kv Channels by Sevoflurane: Insights into the Structural Basis of Inhaled Anesthetic Action." (2015). *Department of Neuroscience Faculty Papers*. Paper 17.  
[https://jdc.jefferson.edu/department_neuroscience/17](https://jdc.jefferson.edu/department_neuroscience/17)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neuroscience Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Qiansheng Liang, Warren D Anderson, Shelly T Jones, Caio S Souza, Juliana M Hosoume, Werner Treptow, and Manuel Covarrubias
RESEARCH ARTICLE

Positive Allosteric Modulation of Kv Channels by Sevoflurane: Insights into the Structural Basis of Inhaled Anesthetic Action

Qiansheng Liang1, Warren D. Anderson1, Shelly T. Jones1, Caio S. Souza3, Juliana M. Hosoume3, Werner Treptow3, Manuel Covarrubias1,2*

1 Department of Neuroscience, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America, 2 Farber Institute for Neuroscience, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America, 3 Laboratório de Biologia Teórica e Computacional, Departamento de Biologia Celular, Universidade de Brasília, Brasília, Brasil

* Manuel.Covarrubias@jefferson.edu

Abstract

Inhalational general anesthesia results from the poorly understood interactions of haloethers with multiple protein targets, which prominently includes ion channels in the nervous system. Previously, we reported that the commonly used inhaled anesthetic sevoflurane potentiates the activity of voltage-gated K\(^+\) (Kv) channels, specifically, several mammalian Kv1 channels and the \textit{Drosophila} K-Shaw2 channel. Also, previous work suggested that the S4-S5 linker of K-Shaw2 plays a role in the inhibition of this Kv channel by n-alcohols and inhaled anesthetics. Here, we hypothesized that the S4-S5 linker is also a determinant of the potentiation of Kv1.2 and K-Shaw2 by sevoflurane. Following functional expression of these Kv channels in \textit{Xenopus} oocytes, we found that converse mutations in Kv1.2 (G329T) and K-Shaw2 (T330G) dramatically enhance and inhibit the potentiation of the corresponding conductances by sevoflurane, respectively. Additionally, Kv1.2-G329T impairs voltage-dependent gating, which suggests that Kv1.2 modulation by sevoflurane is tied to gating in a state-dependent manner. Toward creating a minimal Kv1.2 structural model displaying the putative sevoflurane binding sites, we also found that the positive modulations of Kv1.2 and Kv1.2-G329T by sevoflurane and other general anesthetics are T1-independent. In contrast, the positive sevoflurane modulation of K-Shaw2 is T1-dependent. \textit{In silico} docking and molecular dynamics-based free-energy calculations suggest that sevoflurane occupies distinct sites near the S4-S5 linker, the pore domain and around the external selectivity filter. We conclude that the positive allosteric modulation of the Kv channels by sevoflurane involves separable processes and multiple sites within regions intimately involved in channel gating.

PLOS ONE | DOI:10.1371/journal.pone.0143363 November 24, 2015 1/2
Introduction

Every year, millions of patients around the world undergo general anesthesia to perform major surgeries. However, the mechanisms of general anesthesia, which involve multiple targets, are poorly understood. Also, although general anesthesia is considered generally safe, the drugs currently used lack specificity and have narrow therapeutic indices. Thus, it is necessary to understand anesthesia at all levels to help develop specific, effective and less toxic general anesthetics. Diverse ion channels in the nervous system are likely to be major targets of general anesthetics \[1\]. Among them, neurotransmitter-gated ion channels and non-gated K⁺ channels have received most of the attention \[1, 2\]; however, recent work continues to suggest that voltage-gated ion channels are also important players in general anesthesia \[3–7\].

In particular, recent discoveries have reassessed the likely role of certain Kv1 channels in general anesthesia \[7–9\]. Kv1.2 channels encoded by \emph{Kcna2} gene are widely expressed in the brain and mainly localize in the axon initial segment, the juxtaparanodal region of myelinated axons and axon terminals \[10–12\]. In these locations, heteromultimeric Kv channels including Kv1.1 and Kv1.2 subunits help regulate action potential threshold, repolarization, propagation and firing patterns \[12\]. \emph{Kcna2}-null mice exhibit a severe brainstem seizure phenotype, which is often lethal \[12\]. The findings of Alkire et al. \[8\] and Lioudyno et al. \[9\] are especially significant. Whereas the first study found that infusion of an anti-Kv1.2 antibody into the CMT of the rat reverses anesthesia, the second reported a similar result upon infusion of a specific neurotoxin to block Kv1.1, Kv1.3 and Kv1.6 channels. Moreover, tonic firing of action potentials in neurons of the CMT is inhibited by sevoflurane, which lengthens the interspike interval, and this inhibition is prevented by the aforementioned Kv1-specific neurotoxin.

Sevoflurane is commonly used in human general anesthesia and is a unique positive modulator of several Kv1 channels and the \emph{Drosophila} K-Shaw2 channel in heterologous expression systems \[7, 9\]. At relevant concentrations, it induces a negative shift in the conductance-voltage relation and increases the maximum conductance. By contrast, most other common general anesthetics either interact weakly or inhibit K⁺ channels (namely, K-Shaw2). Since K⁺ channel activity opposes excitation, the unique potentiation of Kv channels by sevoflurane could contribute to anesthesia. Here, we investigated the structural basis of this positive modulation in the mammalian Kv1.2 channel. Previous work strongly implicated the S4-S5 linker as a determinant of the inhibition of K-Shaw2 by general anesthetics \[6, 13\]. The S4-S5 linker connects the voltage-sensing domain to the pore domain of the Kv channels and is responsible for the electromechanical coupling that controls voltage-dependent gating \[14, 15\]. In this study, we investigated the contributions of the S4-S5 linker to the positive modulation of the Kv1.2 and K-Shaw2 channels by sevoflurane. The results revealed that discrete structural changes in this linker drastically affect the response of these Kv channels to the anesthetic by altering electromechanical coupling. Other results strongly suggest additional novel sites, which are necessary to fully explain the modulation of Kv channels by sevoflurane. Supporting a multisite model of general anesthetic action, molecular dynamics, docking simulations and free energy estimations demonstrate two significant classes of sevoflurane binding sites. One set in the pore domain (including the C-terminal side of the S4-S5 linker) and another near the external selectivity filter of the Kv1.2 channel. We propose that positive multisite allosteric modulation of Kv channel gating by sevoflurane plays a significant role in general anesthesia.
Materials and Methods

Molecular biology and heterologous expression

Plasmid maintenance, mutagenesis, sequence, RNA synthesis and oocyte microinjection were carried out as previously described [6, 7].

Ethics Statement

*Xenopus laevis* surgeries were performed according to a protocol approved by the Thomas Jefferson University IACUC.

Electrophysiology

Whole-oocyte currents were recorded at room temperature (21–23°C) under two-electrode voltage-clamp conditions (OC-725C, Warner Instrument, Hamden, CT) according to established procedures [6, 7]. Data acquisition, leak subtraction and initial analysis were performed using pClamp 9.2 and 10.3 (Molecular Devices, Sunnyvale, CA). The pipette was filled with 3 M KCl. The extracellular solution was ND96 (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 2.5 sodium pyruvate, adjusted to pH 7.4 with NaOH. ND96 and n-butanol were delivered using a gravity-driven perfusion system. Volatile anesthetics were delivered manually using a Hamilton gastight syringe (Hamilton, Reno, NV). The preparation and dilution of all drugs were done as previously described [6, 7].

Data analysis

Data analysis, plotting and curve-fitting were performed in Origin 9.1 (OriginLab, Northampton, MA).

*G-V relations.* Peak chord conductance ($G = I/(Vc-Vr)$) was determined assuming -95 mV as the reversal potentials ($Vr$). $I$ is the peak current and $Vc$ is the command voltage. $G-V$ relations were then described by assuming this form of the Boltzmann equation:

$$G = \frac{G_{\text{max}}}{1 + e^{(Vc - V_{1/2})/k}}$$

or the double Boltzmann equation:

$$G = \frac{G_{\text{max1}}}{1 + e^{-(Vc - V_{1/2})/V_{1/2}}} + \frac{G_{\text{max2}}}{1 + e^{-(Vc - V_{1/2})/V_{1/2}}}$$

where $G_{\text{max}}$ is the maximum conductance; $V_{1/2}$ is the voltage at which the conductance is at 50% of its maximal amplitude; and $k$ is the slope factor. The following equation was used to calculate the equivalent gating charge: $z = RT/Fk = 25.5/k$, where $R$, $T$ and $F$ are the gas constant, absolute temperature and Faraday constant, respectively. The $V_{\text{med}}$ was also determined to evaluate multiphasic $G-V$ relations in a curve fitting-independent manner. $V_{\text{med}}$ is the voltage at which the total conductance ($G_{\text{max1}} + G_{\text{max2}}$) is at its midpoint (median). This determination allowed semiquantitative assessment of multiphasic $G-V$ relation shifts without the ambiguity typically associated with curve-fitting involving a large number of correlated adjustable parameters.

All $G-V$ data were obtained from paired sets (same oocyte in the absence and presence of sevoflurane). Measurement of the control $G-V$ relation was followed by determination of a stable response to sevoflurane (current evoked by a depolarizing step to +60 mV, before and after
exposure to sevoflurane) and subsequent measurement of the experimental $G$-$V$ relation. All parameters extracted from the analysis of these relations were compared in a pairwise manner.

To display the results from different oocytes and estimate the magnitude of relative changes (before and after exposure to sevoflurane), individual $G$-$V$ relations were normalized to the control $G_{\text{max}}$ before exposure to sevoflurane ($G/G_{\text{max}}$). Accordingly, a relative $G/G_{\text{max}} = 1$, $<1$ and $>1$ indicates no change, inhibition and potentiation, respectively (Table A in S1 File). Conductance ratio ($G_{\text{Sevo}}/G_0$, conductance in the presence of sevoflurane over control conductance) vs. voltage plots were additionally generated to directly visualize the $G$-$V$ relation change (e.g., Fig 1C). All results were reported as mean ± SEM, and the paired Student $t$-test was used to evaluate the statistical significance of apparent differences, unless stated otherwise.

Concentration-response relations. Normalized dose-inhibition relations were described by assuming this form of the Hill equation:

$$\frac{I}{I_0} = A_1 + \frac{x^{nH}}{K^{nH} + x^{nH}}$$

or a double Hill equation:

$$\frac{I}{I_0} = 1 + \frac{1 + A_1}{1 + \left(\frac{x}{nH}\right)^{nH}} + \frac{1 + A_2}{1 + \left(\frac{x}{nH}\right)^{nH}}$$

where, $I/I_0$ is the normalized current and $x$ is the drug concentration, $K$ (apparent dissociation equilibrium constant) is the drug concentration that induces 50% inhibition/potentiation, and $nH$ is the index of cooperativity or Hill coefficient (Table 1). We do not report SEM for the estimated best-fit Hill equation parameters because complete concentration-response relations and the corresponding best-fit function cannot be constructed from an individual oocyte. Although the action of all anesthetics tested is generally reversible [7], it is often difficult to obtain complete washout of inhaled anesthetics when testing multiple concentrations on the same oocyte. This complication would produce a cumulative effect, which distorts the concentration-response relation. To avoid this problem, each data point on the concentration-response relation represents the mean ± SEM from several independent determinations on different oocytes at the indicated concentrations. For each anesthetic, therefore, there is only one best-fit estimate that collectively describes the combined results from several oocytes individually tested at different concentrations. This approach has produced reproducible results as reported previously [6, 7].

Computational Methods

Kv1.2 models in the closed/resting and open/activated states were obtained from Delemotte et al. [16] and Treptow & Tarek [17]. Each model was previously acquired via molecular dynamics (MD) simulations of the published x-ray crystal structure [18]. Details and validation of the models are as reported in the original papers mentioned above. Structural models of the Kv1.2-G329T mutant were built on the basis of the mentioned Kv1.2 constructs using the psfgen package implemented in VMD [19]. After insertion in a lipid bilayer, each of the structures was equilibrated by MD runs using the program NAMD 2.9 [20] and applying CHARMM 36 force field [21]. Specifically, sevoflurane molecules were then docked against the generated ensemble of membrane-equilibrated channel structures in order to explore putative binding sites using AutoDock Vina [22]. The Linear Interaction Energy (LIE) method [23] was adopted for calculation of the binding free energies and, thus, the corresponding binding constants. Assuming that the predicted binding sites act independently, these binding constants...
were computed for individual sites in different functional conformations. Additional details are provided under S1 File.

Results

Screening the effects of general anesthetics on the Kv1.2 current

Previous studies showed that several heterologously expressed Kv1 channels are potentiated by anesthetic concentrations of sevoflurane [7, 9]. This modulation results primarily from shifting the G-V relation to the left and increasing the \( G_{\text{max}} \) (e.g., Kv1.2; Fig 1). Sevoflurane shifts the Kv1.2 \( V_{1/2} \) by -4 mV and increases the \( G_{\text{max}} \) by 13% (Figs 1A, 1B and 2A; Table A in S1 File). A close examination of the Kv1.2 \( G_{\text{Sevo}}/G_0 \)–voltage relation also shows a substantial sevoflurane-induced potentiation of the conductance at -30 mV (~180%) and a sustained potentiation at positive membrane potentials, which corresponds to the increase in \( G_{\text{max}} \) (Fig 1C). The potentiation at -30 mV is particularly significant because it is within the range where sevoflurane could affect action potential firing.

To additionally screen isoflurane, halothane, chloroform, propofol and \( n \)-butanol, we tested their effects on the Kv1.2 current at +60 mV (Fig 3). Sevoflurane and isoflurane (1 mM) modestly potentiate the Kv1.2 conductance by 12.4 ± 1.7% and 11.5 ± 3.1%, respectively (Fig 3B). For sevoflurane, \( K \) and \( n_{14} \) are 360 \( \mu \)M and 3.3, respectively, which demonstrates relevant
pharmacological potency and apparent cooperativity (Fig 3B and Table 1). Potentiation by isoflurane was already maximal at 100 μM and apparent binding parameters were not estimated. By contrast to sevoflurane and isoflurane, halothane, chloroform and propofol displayed only modest inhibitory effects, while high concentrations of n-butanol produced a more robust inhibition (Fig 3B). Focusing on sevoflurane, we noticed that the previously reported potentiation of K-Shaw2 at +60 mV is ~3-fold greater than that of Kv1.2 [7]. Based on earlier work [6], we hypothesized that differences in the linker connecting the voltage-sensing domain to the pore domain (S4-S5 linker) might explain the differential responses to sevoflurane.

|                 | $K_1$ (mM) | $n_{H1}$ | $A_1$ | $K_2$ (mM) | $n_{H2}$ | $A_2$ |
|-----------------|------------|----------|-------|------------|----------|-------|
| **Kv1.2**       |            |          |       |            |          |       |
| Sevofurane      | 0.36       | 3.3      | 1.13  |            |          |       |
| n-butanol       | 78.4       | 1.3      |       |            |          |       |
| **Kv1.2 FRAKT** |            |          |       |            |          |       |
| Sevofurane      | 0.33       | 2.0      | 1     | 1.45       | 4.0      | 2.50  |
| isoflurane      | 0.23       | 2.2      | 1     | 0.47       | 9.4      | 1.24  |
| Halothane       | 0.16       | 1.6      | 1     | 0.63       | 7.9      | 1.24  |
| Propofol        | 0.02       | 2.2      | 2.89  |            |          |       |
| n-butanol       | 100.5      | 1.5      |       |            |          |       |
| **ΔT1-Kv1.2 FRAKT** |          |          |       |            |          |       |
| Sevofurane      | 0.32       | 2.9      | 1     | 1.84       | 3.8      | 3.17  |
| isoflurane      | 0.22       | 1.2      | 1     | 0.40       | 3.4      | 1.96  |
| Halothane       | 0.23       | 1.0      | 1     | 0.77       | 3.4      | 0.93  |
| Propofol        | 0.02       | 1.7      | 2.66  |            |          |       |
| n-butanol       | 91.9       | 1.6      |       |            |          |       |
| **Kv1.2 G329T** |            |          |       |            |          |       |
| Sevofurane      | 0.40       | 1.6      | 1     | 2.2        | 2.8      | 2.20  |
| **K-Shaw2**     |            |          |       |            |          |       |
| Sevofurane      | 0.06       | 1        | 0.59  | 4          | 1        | 1.23  |
| isoflurane      | 1.69       | 2.1      |       |            |          |       |
| Halothane       | 0.26       | 1.3      |       |            |          |       |
| Chloroform      | 0.70       | 1.4      |       |            |          |       |
| Propofol        | 0.06       | 1.6      |       |            |          |       |
| n-butanol       | 10.1       | 1.8      |       |            |          |       |
| **ΔT1-K-Shaw2** |            |          |       |            |          |       |
| Halothane       | 0.38       | 1.4      |       |            |          |       |
| n-butanol       | 16.4       | 1.5      |       |            |          |       |

* Sevoflurane tested at -20 mV, from Barber et al. [7].

doi:10.1371/journal.pone.0143363.t001

A single amino acid substitution in the Kv1.2 S4-S5 linker (G329T) confers dramatic potentiation by general anesthetics

To investigate the role of the S4-S5 linker in the modulation of Kv1.2 by general anesthetics, we focused on fourteen residues between positions 317 and 330 in K-Shaw2. Within the equivalent region in Kv1.2, there are six substitutions (Fig 4A). The Kv1.2-G319I mutation is, however, lethal (not shown). Therefore, to test the impact of the remaining differences, we converted the S4-S5 linker of Kv1.2 into that of K-Shaw2 between the corresponding Kv1.2 positions.
Potentiation Mechanism of Kv1.2 by Sevoflurane

Fig 2. Analysis of G-V relations from Kv1.2, ΔT1-Kv1.2, K-Shaw2, K-Shaw2 T330G and ΔT1-K-Shaw2.

(A) Best-fit Boltzmann parameters ($V_{1/2}$, $z$ and $G_{\text{max}}$) from individual paired measurements before (Ctr) and after exposure to 1 mM sevoflurane (Sevo). Each pair of symbols connected by a solid line represents an individual paired experiment (Materials and Methods). The $G_{\text{max}}$ graphs depict raw values before normalization (in mS). The P value resulting from a paired Student-t test is shown above each graph, and the red marks indicate the mean values of the sample. (B)–(E) are as described for panel A. The number oocytes examined for each Kv channel was 6, 6, 4, 6 and 6, respectively.

doi:10.1371/journal.pone.0143363.g002
(residues 319–329) to create the Kv1.2-FRAKT chimera. Kv1.2-FRAKT currents evoked by a depolarizing step to +60 mV exhibit a dramatically different pattern of responses to various general anesthetics (Fig 4B and 4C). Sevoflurane, isoflurane, halothane, chloroform and propofol all potentiate the conductance to various degrees, while the inhibitory response to n-butanol remained unaffected. Also, the concentration-potentiation relations for sevoflurane and n-butanol exhibit complex profiles, which are reminiscent of the previously described potentiation of the K-Shaw2 channel by sevoflurane [7]. The concentration dependence of the potentiation is a biphasic phenomenon, occurring gradually at low concentrations and sharply at higher concentrations (Fig 4C). To empirically characterize this behavior, we assumed two classes of independent binding sites exhibiting (Materials and Methods; Fig 4C): 1) apparent high affinity and no cooperativity ($n_H \approx 1$); and 2) apparent low affinity and highly cooperative
interactions ($n_{H} >>1$). Although propofol is the most potent, sevoflurane exhibits the highest efficacy followed by isoflurane, halothane and chloroform (Fig 4C and Table 1). Maximum potentiation by propofol, isoflurane and halothane is, however, similar (2.7 to 3.3-fold above control; Table 1). Although the S4-S5 mutations conferred enhanced potentiation of Kv1.2 by sevoflurane that is similar to that previously observed with K-Shaw2, they also introduced novel potentiation by other general anesthetics. Thus, discrete structural changes in the S4-S5 region.

Fig 4. Modulation of Kv1.2 FRAKT by general anesthetics. (A) Sequence alignment of the S4-S5 linker from K-Shaw2 (314–332) and Kv1.2 (313–331) channels. Starting and ending residue numbers of the shown segments are indicated. In Kv1.2, the blue colored residues were swapped for the red colored residues in K-Shaw2 to create the Kv1.2 FRAKT mutant channel. (B) Effects of general anesthetics on whole-oocyte Kv1.2-FRAKT currents evoked by a voltage step to +60 mV from a holding voltage of -100 mV. Black, red and grey current traces correspond to control, anesthetic-exposed, and washout, respectively. The scale bars indicate 50 ms and 0.5 μA. (C) Concentration-response relations of various general anesthetics acting on the Kv1.2 FRAKT channel. Solid lines are the best fits assuming the Hill equation (propofol and n-butanol) or a double Hill equation (sevoflurane, isoflurane, and halothane) (Materials and Methods). Due to the small magnitude of the chloroform results, no reliable Hill equation fit could be obtained. N = 5–8 oocytes for each concentration. Best-fit parameters are summarized in Table 1.
linker can dramatically influence the ways in which general anesthetics interact with Kv channels. Since sevoflurane is clinically relevant and is the most efficacious positive modulator on Kv1.2-FRAKT and K-Shaw2, we focused on this anesthetic to dissect the structural basis of the potentiation.

To determine the specific amino acid(s) responsible for the dramatic sevoflurane potentiation of Kv1.2-FRAKT, we tested each substitution individually by creating the following Kv1.2 mutants: L321F, K322R, M325A, R326K and G329T. Whereas the potentiation of L321F, K322R, M325A, R326K is similar to that of wild type Kv1.2, G329T exhibited dramatic potentiation not significantly different from that of Kv1.2-FRAKT (two-way ANOVA, $P > 0.05$; Fig 5 and Table 1). These results suggest that a single residue in the S4-S5 linker is a critical determinant of the potentiation of the Kv1.2 current by sevoflurane.

Kv1.2-FRAKT and Kv1.2-G329T exhibit novel voltage dependent gating

The G329T mutation could have affected voltage-dependent gating and thereby allosterically (depending on conformation) influence the interaction of sevoflurane with the channel. Although the mutations do not appear to have gross effects on the overall current kinetics, Kv1.2-FRAKT and G329T dramatically remodel the G-V relation (Materials and Methods). Within a narrow range of membrane potentials (10–20 mV), the wild type Kv1.2 G-V relation sharply rises to the maximum conductance ($G_{\text{max}}$) between +20 and +40 mV (Fig 1B). By contrast, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T rise to the $G_{\text{max}}$ in a more gradual manner and exhibit two distinct components (Fig 6A). These G-V relations approach $G_{\text{max}}$ at voltages $> +100$ mV and require the sum of at least two Boltzmann terms to adequately describe them (Fig 6B). Moreover, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T have similar profiles, albeit there are some quantitative differences (Fig 6; Table A in S1 File). For Kv1.2-FRAKT and Kv1.2-G329T: the median voltages ($V_{\text{med}}$) are 22±2 and 28±2 mV, respectively (Fig 6). Relative to Kv1.2-FRAKT, Kv1.2-G329T modestly depolarizes $V_{1/2,1}$ by ~13 mV and induces a 16 mV negative shift of $V_{1/2,2}$ (Fig 6; Table A in S1 File). The corresponding equivalent gating charges ($z_1$ and $z_2$) increase from 2.7±0.1 to 4.8±0.1 e$_0$, and from 0.9±0.1 to 1.5±0.1 e$_0$ (Fig 6; Table A in S1 File). Nevertheless, among all individual FRAKT mutations, G329T is the only one that closely recapitulates the behavior of the Kv1.2-FRAKT indicating that it plays the most critical role in determining the novel gating phenotype of the chimera. Individual mutations of other residues (L321F, K322R, M325A, R326K) had little to no effect on Kv1.2 G-V relation (Fig A in S1 File).

Upon exposure to 1 mM sevoflurane, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T display changes that are qualitatively similar to those observed with Kv1.2 wild type; however, the net magnitudes are substantially larger (Fig 7A and 7B; Table A in S1 File). $\Delta V_{\text{med}}$ shifts to the left by ~15 and ~20 mV, respectively. On Kv1.2-FRAKT, sevoflurane induced small–modest changes in $V_{1/2,1}$, $z_1$ and $z_2$; however, sevoflurane most noticeably doubles the total conductance ($G_{\text{TOTAL}} = G_{\text{max1}} + G_{\text{max2}} = 2.07$) as a result of increasing $G_{\text{max1}}$ (0.37 to 0.99) and $G_{\text{max2}}$ (0.63 to 1.07) (Fig 7A; Table A in S1 File). Kv1.2-G329T, in contrast, displayed more selective effects on the bimodal G-V relation. The $V_{1/2,1}$ and $z_1$ are not affected, whereas the sevoflurane-induced negative $\Delta V_{1/2,2}$ is substantial (~11 mV, with no change in $z_2$). Additionally, as found with Kv1.2-FRAKT, sevoflurane nearly doubles the total Kv1.2-G329T conductance ($G_{\text{TOTAL}} = 1.89$) (Fig 7B; Table A in S1 File). These results demonstrate that G329T alone markedly alters gating and concomitantly enhances the potentiation by sevoflurane, suggesting a strong link between voltage-dependent gating and anesthetic action.
K-Shaw2-T330G eliminates the sevoflurane-induced voltage-dependent shift without affecting the sevoflurane-induced increase in $G_{\text{max}}$. Since G329 in Kv1.2 critically controls voltage-dependent activation and keeps positive modulation by sevoflurane in check, we asked whether the reverse mutation in K-Shaw2 (T330G) would inhibit the naturally robust potentiation of this Kv channel by sevoflurane. In contrast to Kv1.2-G329T, K-Shaw2-T330G does not significantly affect the $G-V$ relation (Fig 2; Table A in S1 File); however, it abolishes the sevoflurane-induced leftward shift of the $G-V$ relation (Figs 2, 8A and 8B; Table 1; Table A in S1 File). Accordingly, T330G dramatically inhibits the potentiated conductance ratio ($G_{\text{Sevo}}/G_0$) from ~10 to ~1.3 at -40 mV (Fig 8C). However, the sevoflurane-induced increase in the $G_{\text{max}}$ of K-Shaw2-T330G and wild type K-Shaw2 are very similar (1.4- and 1.6-fold, respectively; Table A in S1 File). Accordingly, the $G_{\text{Sevo}}/G_0$ of wild type and mutant channels converge toward a similar value at +100 mV (~1.5; Fig 8C). This
result suggests that the positive modulation induced by sevoflurane has two separable components. One depends on the role of a specific residue in the S4-S5 linker that controls voltage-dependent gating, whereas the other is independent of that residue and namely affects the G_{\text{max}}.

The role of the T1 domain on the modulations of Kv1.2, Kv1.2-FRAKT and K-Shaw2 by sevoflurane

Previous studies strongly suggest that the intracellular regulatory T1 domain of Kv channels plays a significant role in gating [24–28]. Thus, we asked whether the T1 domain might also contribute to the positive modulation of Kv1.2, Kv1.2-FRAKT and K-Shaw2, by sevoflurane. In ΔT1-Kv1.2 and ΔT1-Kv1.2-FRAKT, residues 2–122 are missing; and ΔT1-K-Shaw2 lacks residues 2–155. ΔT1-Kv1.2 and ΔT1-Kv1.2-FRAKT exhibited G-V relations and responses to general anesthetics that are similar to those from their full-length counterparts (Figs 2B, 7C, 9A and 9B; Fig B and Table A in S1 File). Sevoflurane shifted the ΔT1-Kv1.2 V_{1/2} by -4 mV, and increased the G_{\text{max}} by 10%. It also shifted the ΔT1-Kv1.2-FRAKT V_{\text{med}} by -19 mV and nearly doubled the G_{\text{TOTAL}} (1.9-fold). By contrast, ΔT1-K-Shaw2 exhibited a substantially leftward shifted G-V relation (-48 mV; data not shown) and no positive effect of sevoflurane on V_{1/2} and G_{\text{max}} (Fig 2; Table A in S1 File). These results suggest that voltage-dependent gating of Kv1.2 and Kv1.2-FRAKT and their modulation by general anesthetics are independent of the T1 domain. K-Shaw2 gating and its positive modulation by sevoflurane are, however, completely dependent on the presence of the T1 domain, suggesting specialized interactions between the T1 domain and the gating apparatus of the K-Shaw2 channel. Thus, we can infer that the dual positive modulation of the Kv1.2 channel by sevoflurane (leftward shifted G-V relation and increased G_{\text{max}}) only implicates regions directly involved in gating (the voltage-sensing and pore domains). Based on this outcome, we created minimal atomic models of...
Fig 7. Analysis of bimodal G-V relations from Kv1.2 FRAKT, Kv1.2 G329T and ΔT1-Kv1.2 FRAKT. (A) Best-fit double Boltzmann parameters ($V_{1/2,1}$, $G_{max,1}$, $V_{1/2,2}$, $G_{max,2}$) and $V_{med}$ from individual paired measurements before (Ctr) and after exposure to 1 mM sevoflurane (Sevo). Each pair of symbols connected by a solid line represents an individual paired experiment (Materials and Methods). The $G_{max}$ graphs depict raw values before normalization (in mS). The $P$ value resulting from a paired Student-t test is shown above each graph, and the red marks indicate the mean values of the sample. (B)–(C) are as described for panel A. The number of oocytes examined for each Kv channel was 6, 4, 5, respectively.

doi:10.1371/journal.pone.0143363.g007
ΔT1-Kv1.2 and ΔT1-Kv1.2 G329T to explore putative in-silico interaction sites in the transmembrane regions of the channel.

Putative sevoflurane binding sites in ΔT1-Kv1.2 and ΔT1-Kv1.2-G329T

The results so far demonstrate that 1) sevoflurane potentiates the Kv1.2 current with relevant apparent affinity and cooperativity and is independent of the T1 domain; 2) sevoflurane interacts with two independent classes of sites in K-Shaw2, Kv1.2-FRAKT and Kv1.2-G329T (with apparent high and low affinities); 2) G329T is sufficient to confer dramatic positive modulation by sevoflurane and other general anesthetics; 3) the potentiation of Kv1.2-G329T by sevoflurane resembles the action of this anesthetic on K-Shaw2; 4) G329T fully recapitulates the electrophysiological and pharmacological phenotype of the Kv1.2-FRAKT chimera, which is
also independent of the T1 domain; 5) the reverse K-Shaw2-T330G mutation at a position equivalent to that of G329 in Kv1.2 nearly eliminates the sevoflurane-induced leftward shift of the K-Shaw2 G-V relation. These results suggest that G329 in the S4-S5 linker plays a key role controlling the potentiation of the Kv1.2 current by sevoflurane. In the light of these observations, we explored putative sites of sevoflurane action in the Kv1.2 channel to help elucidate a working mechanism of anesthetic action. To identify putative sevoflurane binding sites with atomic resolution, we applied docking and MD-based free-energy calculations. Specifically, we docked sevoflurane against an ensemble of 120 membrane-equilibrated structures of ΔT1-Kv1.2 and ΔT1-Kv1.2-G329T in the activated-open and resting-closed conformations (Materials and Methods and S1 File). The sampling of an ensemble accounts for the molecular flexibility of the protein. Then, starting from sevoflurane-bound channel structures, we carried out free-energy calculations using the LIE method to resolve site-specific affinities of sevoflurane (S1 File). This calculation assumes that individual sites are independent. Also, because electrophysiological experiments do not measure actual binding of the anesthetics to the Kv channels, we made no attempt to quantitatively compare an “apparent” affinity (electrophysiological estimate) against the calculated affinities of multiple putative sites (LIE estimates). To learn about relative properties of putative sites, we only compared calculated affinities between different classes of sites in putative resting-closed and activated-open conformations.

Sevoflurane is found at four distinct locations on the Kv channel structures, hereafter called sites 1–4 (Fig 10A). Sites 1 and 2 are located near the S4-S5 linker at the internal face of the channel; site 3 is formed in the S5-S6 interface of adjacent subunits; and site 4 involves discrete pockets around the selectivity filter at the extracellular face of the channel. Sites 1 and 2 are near G329T in the mutant channel (Fig 10B). Despite a similar pattern of binding sites in Kv1.2 and Kv1.2-G329T, the LIE analysis of interaction energies revealed subsets of non-overlapping sites with relatively low and high affinities (Fig 10C; Table B in S1 File). Sites 1–3 involving the S4-S5 linker and pore domain exhibit relatively low-affinities with binding constants ranging between 0.01–0.2 mM⁻¹; and site 4 around the selectivity filter exhibits relatively high-affinity ranging between 0.3–0.4 mM⁻¹. In addition, the binding constants of sites 1 and 3

Fig 10. Putative sevoflurane binding sites in the Kv1.2 channel. (A) Representation of four distinct sevoflurane binding locations on Kv1.2: site 1 (light blue), 2 (blue), 3 (black) and 4 (purple). Each pair of subunits is represented in green and orange. Mutation G329T is highlighted yellow. (B) Close-up view of ligand binding sites and mutation. Note that site 2 is in close proximity to the mutated residue G329T. (C) Binding constants of individual sevoflurane sites. These estimates were obtained using the LIE method as described under S1 File. O and C stand for activation-open and resting-closed conformations of the channel.

doi:10.1371/journal.pone.0143363.g010
display modest conformation dependence, with a slight preference for the open state in Kv1.2-G329T. In contrast, the site 2 binding constants in the resting-closed conformation are ~7-fold greater than in the fully open conformation, for both wild type Kv1.2 and Kv1.2-G329T. Site 4 exhibits the largest binding constants, but no conformation dependence (Fig 10C; Table B in S1 File). These results are consistent with a scenario in which the modulation of Kv1.2 channels by sevoflurane results from multiple interactions with distinct classes of sites. A subset of these sites is possibly responsible for leftward shifting the G-V relation and another potentially contributing to the net increase in $G_{\text{max}}$. However, since the calculated binding constants of wild type Kv1.2 and Kv1.2-G329T are generally similar (ranging between 0.02–0.4 mM$^{-1}$), additional factors probably determine the larger efficacy of sevoflurane acting on the mutant channel.

**Discussion**

**Distinct gating processes in Kv channels**

Shaker-related Kv1 channels undergo complex and strongly voltage-dependent activation gating involving sequential transitions between multiple closed states and a final cooperative opening step [29–31]. This mechanism has two major steps. The first corresponds to a major conformational change of the voltage sensors, which unlocks the gating machinery; and the second corresponds to a final cooperative rearrangement of the voltage sensors, which ultimately opens the intracellular activation gate [32, 33]. Whereas the first step is associated with movement of a large gating charge ($14–16 \ e_0$), the second only involves movement of a small gating charge (~1 $e_0$). Therefore, tightly coupled voltage-dependent gating is typically dominated by the first component. The previously investigated Shaker-ILT voltage sensor mutant clearly unveiled the second step by greatly shifting its voltage dependence toward depolarized voltages [32, 33]. The K-Shaw2 channel is a special case where the weakly voltage-dependent component is sufficient to control activation gating and can be described as a simple first-order equilibrium [34, 35]. Here, we showed that mutations that converted the S4-S5 linker of Kv1.2 into that of K-Shaw2 exhibit a Shaker-ILT-like gating phenotype, albeit the separation of the two activation components is further exaggerated. These mutations do not have much effect on the first sharp component of the G-V relation (Table A in S1 File). In contrast, the second gating component of the mutant G-V relations becomes clearly evident as a result of a robust depolarizing shift of its voltage dependence. Remarkably, the profile and voltage dependence of this depolarized component resembles the K-Shaw2 G-V relation. We propose that the G329T mutation at the C-terminal end of the S4-S5 linker induces these changes by greatly reducing the weakly voltage-dependent equilibrium constant of the cooperative opening transition. Such a reduction could directly result from hampering protein backbone flexibility caused by the glycine to threonine substitution at a critical position. The flexibility conferred by glycine at this position might create a critical pivot point generally conserved in a majority of Kv channels (Fig C in S1 File). The rare natural substitution of glycine for threonine at the equivalent position in wild type K-Shaw2 might help determine the unusual gating properties of K-Shaw2 and its distinctive strong positive modulation by sevoflurane [7].

**Putative mechanism of sevoflurane action on Kv channels**

The positive modulation of Kv channels by sevoflurane is associated with two separable effects. One shifts the G-V relation leftward and the other increases the $G_{\text{max}}$. Sevoflurane might thus simultaneously influence two separable processes by acting at two distinct sites. We propose that sevoflurane shifts the G-V relation leftward by having a positive influence on the final weakly voltage-dependent component of gating that ultimately controls the opening of the Kv
channel. The anesthetic might achieve this by interacting with the S4-S5 linker and the pore domain. The Kv channel’s S4 voltage sensor transmits its final concerted conformational change to the S4-S5 linker, which in turn acts on the intracellular activation gate to open it [14, 15, 18]. This idea helps explain quantitatively distinct sevoflurane modulations of Kv1.2 and K-Shaw2 channels and how S4-S5 linker mutations have profound effects on the final gating component and the positive modulation by sevoflurane and other general anesthetics. K-Shaw2 gating is dominated by the concerted conformational change transmitted by the S4-S5 linker, (in contrast to more conventional gating in Kv1 channels; see section above), and sevoflurane might selectively influence this process. Therefore, sevoflurane appears to have a greater effect on the voltage dependence of K-Shaw2 than on that of Kv1.2. However, upon introducing the G329T mutation at the C-terminal end of the Kv1.2 S4-S5 linker, the final gating component appears rightward shifted and magnified. Consequently, the potentiation of the Kv1.2-G329T by sevoflurane is also magnified, which seems to namely result from selectively leftward shifting the final gating component. To cause this shift, sevoflurane might increase the equilibrium constant of the opening step by destabilizing the pre-open closed state, as previously proposed for the wild-type K-Shaw2 [6] (see below). Supporting these ideas further, the reverse K-Shaw2 T330G mutation conversely eliminates the sevoflurane-induced leftward shift of the G-V relation, albeit has no significant effect on voltage-dependent gating (Fig 8). Additionally, this experiment surprisingly revealed that T330 is only a critical determinant of the sevoflurane effect on voltage dependence because the T330G mutation did not significantly affect the sevoflurane-induced increase in G_{\text{max}}. This selectivity strongly suggests that another site is independently responsible for the sevoflurane-induced increase in G_{\text{max}}. Given the quick onset and reversibility of the positive modulation [7], we propose that, rather that increasing the number of functional channels, sevoflurane probably increases the maximum open probability and/or the unitary conductance. The potentiation of the ShakerB Kv channel by isoflurane results from the combination of both effects [36]. Further work is needed to investigate the biophysical and molecular underpinnings of the sevoflurane-induced increase in G_{\text{max}}.

Exploring putative sevoflurane binding sites and mechanisms of action in the Kv1.2 channel

We gained more specific insights into sites and mechanisms of sevoflurane action from atomic level simulations of a membrane-equilibrated Kv1.2 model in the resting closed and open states. In silico docking of sevoflurane to these conformations, along with free-energy calculations, revealed putative sites with distinct binding affinities in regions experimentally implicated in anesthetic action by the comparative study of the Kv1.2 and K-Shaw2 channels. Sites 1 and 2 are in close proximity to the S4-S5 linker. Sevoflurane binding to site 2 in Kv1.2 and Kv1.2-G329T is, however, significantly weaker in the open state than in the resting closed state (~7-fold). Thus, a simple stabilization of the open state alone does not explain the sevoflurane-induced leftward shift in the G-V relation. Rather, this shift might result from the crosstalk among various interacting sites, which globally destabilizes the pre-open closed state. Further modeling of sevoflurane binding sites in the pre-open closed state will be necessary to examine this possibility.

Why does Kv1.2-G329T exhibit greater sevoflurane-induced potentiation than the wild type counterpart? The G329T mutation alone might stabilize the pre-open closed state and consequently the voltage dependence of the opening step is better resolved as a separate depolarized gating component of the G-V relation (see above). That is, actual opening of the channel becomes harder. If sevoflurane binds to a pre-open closed state displaying an increased
presence in the G329T mutant, it might have greater influence on its stability. Presumably, binding of sevoflurane to interacting sites in the tetrameric Kv1.2-G329T opposes the negative effect of the mutation by destabilizing the pre-open closed state, which results in the observed sevoflurane-induced leftward shift of the G-V relation’s second gating component. Essentially, sevoflurane might act similarly on wild type Kv1.2. In this case, however, the tight coupling between voltage-dependent activation and channel opening blurs the separation of the gating components in the G-V relation. This implies that, relative to the G329T, the relative availability of binding sites in the pre-open closed state of wild type Kv1.2 is more limited. Therefore, the dynamic range for positive modulation of wild type Kv1.2 by sevoflurane is more restricted and the potentiation less efficacious.

Sharply in contrast to sites 1–3, site 4 located externally around the selectivity filter displays the strongest binding constants (on average, ~5-fold stronger than the highest affinity of site 2), but little state dependence. Binding of sevoflurane to this site is particularly interesting because it might affect the stability of the selectivity filter, which plays a role in a mechanism of Kv channel inactivation [37]. Stabilization of the open conducting conformation of the selectivity filter following sevoflurane binding to site 4 could help explain the sevoflurane-induced increase in the $G_{\text{max}}$. Further experimental validation would, however, be necessary to test this hypothesis. Multiple binding sites with distinct binding constants is consistent with the presence of low- and high-affinity components of the Kv1.2-FRAKT and Kv1.2-G329T concentration-potentiation relations for various inhaled anesthetics (Figs 4 and 5). However, no quantitative relationships could be made at this time.

Surprisingly, the positive modulation of K-Shaw2 by sevoflurane is T1 domain-dependent, whereas that of Kv1.2-FRAKT is not. This observation suggests that other interactions contribute to the ability of sevoflurane to influence the final opening step. Supporting this idea, the T1 domain scaffolding of Kv1.2 and K-Shaw2 channels exhibit significant differences in regions that have been implicated in gating [28, 38].

Concluding remarks

Three major mechanistic conclusions emerge from this study. First, the positive modulation of Kv1.2 channels by general anesthetics depends on a single S4-S5 linker residue (G329). G329T confers dramatic positive modulation by sevoflurane Threonine is the residue naturally found at the equivalent position in the K-Shaw2 (T330), a Kv channel that normally exhibits strong positive modulation by sevoflurane. Underscoring the critical role of T330, the converse mutation T330G abolished voltage-dependent potentiation of K-Shaw2 by sevoflurane without affecting the sevoflurane-induced increase in $G_{\text{max}}$. Such a differential effect suggests separable sites of sevoflurane action, which is consistent with modeling results. The location of G329 and T330 in the S4-S5 linker of these Kv channels suggests that this position is a critical pivot point of voltage-dependent gating. Second, depending on Kv channel specific interactions, the cytoplasmic T1 domain may additionally contribute to the positive modulation of K-Shaw2 by sevoflurane. Third, molecular modeling suggests that positive modulation results from allosteric interactions between sites 1–3, the pore domain and the S4-S5 linker -a critical moving part involved in activation gating. These interactions might favorably influence pore opening. Additionally, binding to site 4 might stabilize the open state. These mechanisms serve as framework to explain how Kv1 channels might play a role in general anesthetic action.

Supporting Information

S1 File. Liang et al Supporting Information.

(DOCX)
Acknowledgments

We thank Drs. Annika F. Barber and Roderic G. Eckenhoff (University of Pennsylvania) for critically reading the manuscript and helpful discussions. W.T. thanks Antonio Pereira De Araujo (University of Brasilia) for comments and discussions. Also, we thank members of the Covarrubias lab for support and feedback throughout the preparation of this work.

Author Contributions

Conceived and designed the experiments: QL WT MC. Performed the experiments: QL WDA STJ CSS JMH. Analyzed the data: QL WDA STJ CSS JMH WT MC. Wrote the paper: QL WT MC.

References

1. Franks NP. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci. 2008; 9(5):370–86. doi:10.1038/nrn2372 PMID: 18425091
2. Kopp Lugli A, Yost CS, Kindler CH. Anaesthetic mechanisms: update on the challenge of unravelling the mystery of anaesthesia. Eur J Anaesth. 2009; 26(10):807–20. doi:10.1097/EJA.0b013e32823ed6b0 PMID: 19494779; PubMed Central PMCID: PMC4277826.
3. Hemmings HC Jr. Sodium channels and the synaptic mechanisms of inhaled anaesthetics. Br J Anaesth. 2009; 103(1):61–9. doi:10.1093/bja/aep144 PMID: 19508978
4. Herold KF, Hemmings HC Jr. Sodium channels as targets for volatile anesthetics. Front Pharmacol. 2012; 3:50. Epub 2012/04/23. doi:10.3389/fphar.2012.00050 PMID: 22479247; PubMed Central PMCID: PMCPmc3316150.
5. Barber AF, Carnevale V, Klein ML, Eckenhoff RG, Covarrubias M. Modulation of a voltage-gated Na+ channel by sevoflurane involves multiple sites and distinct mechanisms. Proc Natl Acad Sci USA. 2014; 111(18):6726–31. Epub 2014/04/23. doi:10.1073/pnas.1405768111 PMID: 24753593; PubMed Central PMCID: PMCPmc4020080.
6. Barber AF, Liang Q, Amaral C, Treptow W, Covarrubias M. Molecular mapping of general anesthetic sites in a voltage-gated ion channel. Biophys J. 2011; 101(7):1613–22. doi:10.1016/j.bpj.2011.08.026 PMID: 21961587
7. Barber AF, Liang Q, Covarrubias M. Novel activation of voltage-gated K+ channels by sevoflurane. J Biol Chem. 2012; 287(48):40425–32. Epub 2012/10/06. doi:10.1074/jbc.M112.405787 PMID: 23038249; PubMed Central PMCID: PMCPmc3504757.
8. Alkire MT, Asher CD, Franciscus AM, Hahn EL. Thalamic microinfusion of antibody to a voltage-gated potassium channel restores consciousness during anesthesia. Anesthesiology. 2009; 110(4):766–73. Epub 2009/03/27. PMID: 19322942.
9. Lioudyno MI, Birch AM, Tanaka BS, Sokolov Y, Goldin AL, Chandy KG, et al. Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics. J Neurosci. 2013; 33(41):16310–22. Epub 2013/10/11. doi:10.1523/jneurosci.0344-13.2013 PMID: 24107962; PubMed Central PMCID: PMCPmc3792466.
10. Trimmer JS, Rhodes KJ. Localization of voltage-gated ion channels in mammalian brain. Annu Rev Physiol. 2004; 66:477–519. PMID: 14977411
11. Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci. 2006; 7(7):548–62. PMID: 16791144
12. Robbins CA, Tempel BL. Kv1.1 and Kv1.2: similar channels, different seizure models. Epilepsia. 2012; 53 Suppl 1:134–41. doi:10.1111/j.1528-1167.2012.03484.x PMID: 22612818.
13. Bhattacharji A, Klett N, Go RC, Covarrubias M. Inhalational anaesthetics and n-alcohols share a site of action in the neuronal Shaw2 K+ channel. Br J Pharmacol. 2010; 159(7):1475–85. doi:10.1111/j.1476-5381.2010.00642.x PMID: 20136839
14. Blunck R, Batulan Z. Mechanism of electromechanical coupling in voltage-gated potassium channels. Front Pharmacol. 2012; 3:166. doi:10.3389/fphar.2012.00166 PMID: 22988442
15. Chowdhury S, Haehnel BM, Chanda B. Interfacial gating triad is crucial for electromechanical transduction in voltage-activated potassium channels. J Gen Physiol. 2014; 144(5):457–67. doi:10.1085/jgp.201411185 PMID: 25311635; PubMed Central PMCID: PMCPmc4210428.
16. Delemotte L, Tarek M, Klein ML, Amaral C, Treptow W. Intermediate states of the Kv1.2 voltage sensor from atomistic molecular dynamics simulations. Proc Natl Acad Sci USA. 2011; 108(15):6109–14. doi: 10.1073/pnas.1102724108 PMID: 21444776; PubMed Central PMCID: PMCPMC3076833.

17. Treptow W, Tarek M. Environment of the gating charges in the Kv1.2 Shaker potassium channel. Biophys J. 2006; 90(9):L64–L6. PMID: 16533847

18. Long SB, Campbell EB, MacKinnon R. Voltage Sensor of Kv1.2: Structural Basis of Electromechanical Coupling. Science. 2005; 309:33–8. PMID: 16002579

19. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33–8. PMID: 8744570.

20. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005; 26(16):1781–802. PMID: 16222654

21. Huang J, MacKerell AD Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013; 34(25):2135–45. doi: 10.1002/jcc.21334 PMID: 23832629; PubMed Central PMCID: PMCPMC3041641.

22. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31(2):455–61. doi: 10.1002/jcc.21334 PMID: 19499576; PubMed Central PMCID: PMCPMC3041641.

23. Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994; 7(3):385–91. PMID: 8177887.

24. Wang G, Covarrubias M. Voltage-dependent gating rearrangements in the intracellular T1-T1 interface of a K+ channel. J Gen Physiol. 2006; 127(4):391–400. PMID: 16533897

25. Wang G, Strang C, Pfaffinger PJ, Covarrubias M. Zn2+-dependent redox switch in the intracellular T1-T1 interface of a Kv channel. J Biol Chem. 2007; 282(16):13637–47. PMID: 17331952

26. Cushman SJ, Nanao MH, Jahng AW, DeRubeis D, Choe S, Pfaffinger PJ. Voltage dependent activation of potassium channels is coupled to T1 domain structure. Nat Struct Biol. 2000; 7(5):403–7. PMID: 10802739

27. Robinson JM, Deutsch C. Coupled tertiary folding and oligomerization of the T1 domain of Kv channels. Neuron. 2005; 45(2):223–32. PMID: 15664174

28. Minor DL, Lin YF, Mobley BC, Avelar A, Jan YN, Jan LY, et al. The polar T1 interface is linked to conformational changes that open the voltage-gated potassium channel. Cell. 2000; 102(5):657–70. PMID: 11007484

29. Schoppa NE, McCormack K, Tanouye MA, Sigworth FJ. The size of gating charge in wild-type and mutant Shaker potassium channels. Science. 1992; 255(5052):1712–5. PMID: 1553560

30. Schoppa NE, Sigworth FJ. Activation of Shaker potassium channels. III. An activation gating model for wild-type and V2 mutant channels. J Gen Physiol. 1998; 111(2):313–42. PMID: 9450946

31. Zagotta WN, Hoshi T, Aldrich RW. Shaker potassium channel gating. III: Evaluation of kinetic models for activation. J Gen Physiol. 1994; 103(2):321–62. PMID: 8189208

32. Pathak M, Kurtz L, Tombola F, Isacoff E. The cooperative voltage sensor motion that gates a potassium channel. J Gen Physiol. 2005; 125(1):57–69. PMID: 15623895

33. Ledwell JL, Aldrich RW. Mutations in the S4 region isolate the final voltage-dependent cooperative step in potassium channel activation. J Gen Physiol. 1999; 113(3):389–414. PMID: 10051516

34. Smith-Maxwell CJ, Ledwell JL, Aldrich RW. Uncharged S4 residues and cooperativity in voltage-dependent potassium channel activation. J Gen Physiol. 1998; 111(3):421–39. PMID: 9482709

35. Smith-Maxwell CJ, Ledwell JL, Aldrich RW. Role of the S4 in cooperativity of voltage-dependent potassium channel activation. J Gen Physiol. 1998; 111(3):399–420. PMID: 9482708

36. Li J, Correa AM. Single-channel basis for conductance increase induced by isoflurane in Shaker H4 IR K+ channels. Am J Physiol—Cell Physiol. 2001; 280(5):C1130–C9. PMID: 11287326

37. Hoshi T, Armstrong CM. C-type inactivation of voltage-gated K+ channels: pore constriction or dilation? J Gen Physiol. 2013; 141(2):151–60. doi: 10.1085/jgp.201210888

38. Bixby KA, Nanao MH, Shen NV, Kreusch A, Bellariny H, Pfaffinger PJ, et al. Zn2+-binding and molecular determinants of tetramerization in voltage-gated K+ channels. Nat Struct Biol. 1999; 6(1):38–43. PMID: 9886290